EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review

Jiaqi Zhai, Xi Gu, Yang Liu, Yueting Hu, Yi Jiang, Zhenyong Zhang

Frontiers in Pharmacology · 21.04.2023 · 14

DOI: 10.3389/fphar.2023.1152934 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 21.04.2023. Verfasst von Jiaqi Zhai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China. Die Arbeit wurde bisher 136-mal zitiert (Crossref) und nennt 165 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Liaoning Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As traditional strategies for cancer treatment, some chemotherapy agents, such as doxorubicin, oxaliplatin, cyclophosphamide, bortezomib, and paclitaxel exert their anti-tumor effects by inducing immunogenic cell death (ICD) of tumor cells. ICD induces anti-tumor immunity through release of, or exposure to, damage-related molecular patterns (DAMPs), including high mobility group box 1 (HMGB1), calreticulin, adenosine triphosphate, and heat shock proteins. This leads to activation of tumor-specific immune responses, which can act in combination with the direct killing functions of chemotherapy drugs on cancer cells to further improve their curative effects. In this review, we highlight the molecular mechanisms underlying ICD, including those of several chemotherapeutic drugs in inducing DAMPs exposed during ICD to activate the immune system, as well as discussing the prospects for application and potential role of ICD in cancer immunotherapy, with the aim of providing valuable inspiration for future development of chemoimmunotherapy.

Schlagwörter

Stichwörter der Autor:innen

antitumor immunitycancer chemoimmunotherapychemotherapeutic drugdamage-related molecular patterns (DAMPs)immunogenic cell death (ICD)

Autor:innen und Institutionen

  • Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.

Förderung

  • Natural Science Foundation of Liaoning Province
  • National Natural Science Foundation of China

Zitieren

APA

Zhai, J., Gu, X., Liu, Y., Hu, Y., Jiang, Y., & Zhang, Z. (2023). Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1152934

Vancouver

Zhai J, Gu X, Liu Y, Hu Y, Jiang Y, Zhang Z. Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1152934

BibTeX
@article{Zhai2023,
  author = {Zhai, Jiaqi and Gu, Xi and Liu, Yang and Hu, Yueting and Jiang, Yi and Zhang, Zhenyong},
  title = {Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1152934}
}
Kostenlos starten →